Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBT: 2010-2025

Historic EBT for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$16.9 million.

  • Northwest Biotherapeutics' EBT fell 0.36% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5.42%. This contributed to the annual value of -$74.3 million for FY2024, which is 22.27% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' EBT is -$16.9 million, which was down 2.02% from -$16.6 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' EBT peaked at -$11.7 million during Q3 2021, and registered a low of -$22.5 million during Q2 2022.
  • In the last 3 years, Northwest Biotherapeutics' EBT had a median value of -$16.9 million in 2024 and averaged -$17.0 million.
  • Examining YoY changes over the last 5 years, Northwest Biotherapeutics' EBT showed a top increase of 78.18% in 2021 and a maximum decrease of 148.49% in 2021.
  • Northwest Biotherapeutics' EBT (Quarterly) stood at -$11.8 million in 2021, then plummeted by 64.00% to -$19.4 million in 2022, then rose by 15.54% to -$16.4 million in 2023, then decreased by 28.09% to -$21.0 million in 2024, then dropped by 0.36% to -$16.9 million in 2025.
  • Its EBT was -$16.9 million in Q3 2025, compared to -$16.6 million in Q2 2025 and -$18.9 million in Q1 2025.